BD will offer Accelerate Diagnostic’s rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
NEWS PROVIDED BY
BD (Becton, Dickinson and Company)
Aug 15, 2022, 06:50 ET
SHARE THIS ARTICLE
Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide
FRANKLIN LAKES, N.J. and TUCSON, Ariz., Aug. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in-vitro diagnostics in microbiology, today announced a worldwide commercial collaboration agreement where BD will offer Accelerate's rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.
Under the agreement, BD will market and sell the Accelerate Pheno® system and Accelerate Arc™ module and associated test kits through its global sales network in territories where products have regulatory approval or registration. These solutions complement BD's existing Clinical Microbiology portfolio and advance the shared goal of both companies to address the global threat of antimicrobial resistance.
"When a patient is very sick, every minute matters," said Brooke Story, president of Integrated Diagnostic Solutions for BD. "Rapid testing can quickly determine if an antibiotic should be used for treatment, and if so, which one. Through our collaboration with Accelerate Diagnostics, we can help clinicians more quickly, efficiently and effectively treat patients, which may lead to a reduction in health care costs and help slow the spread of antimicrobial resistance."
The Accelerate PhenoTest® BC kit is the first test cleared by the U.S. Food and Drug Administration that can deliver both rapid identification and phenotypic antibiotic susceptibility results in hours direct from positive blood cultures. Recent external studies indicate this solution offers results one to two days faster than traditional laboratory methods, which can include culturing samples for 18 to 24 hours, and then performing a susceptibility test that can take eight to 24 hours to result. This enables clinicians to optimize antibiotic selection and dosage specific to the individual patient, days earlier. It is well established in peer-reviewed literature that improving time to optimal therapy benefits both patient outcomes and hospital operations.
The Accelerate Arc™ module is a simple load-and-go system that eliminates the requirement of a subculture for MALDI ID as well as the need for lengthy hands-on time by automating the direct MALDI ID workflow. It is currently US , CE-IVDR and UKCA registered for positive blood cultures.
"With BD's large installed customer base of clinical microbiology systems, this collaboration exponentially increases our global commercial reach and provides numerous ways to increase our market penetration with Pheno and Arc to reach more clinicians and patients," said Jack Phillips, president and CEO of Accelerate Diagnostics. "Beyond the immediate clinical and commercial benefits, we are excited about the opportunity to collaborate with BD as a long-term leader in clinical microbiology."
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistant infections, a leading cause of sepsis. The company's first fully automated platform to provide rapid identification and antimicrobial susceptibility results remains the only solution currently cleared for use with positive blood culture samples by the U.S. FDA.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately
Recent AXDX News
- Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. • PR Newswire (US) • 05/02/2024 01:30:00 PM
- Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. • PR Newswire (US) • 03/07/2024 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:32:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:31:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 12:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:45:17 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/05/2024 08:59:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:59:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:48:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:12:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 09:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 02:20:45 AM
- Form 424B1 - Prospectus [Rule 424(b)(1)] • Edgar (US Regulatory) • 01/23/2024 02:59:53 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:17 AM
- Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement • PR Newswire (US) • 01/19/2024 02:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 12:19:47 PM
- Accelerate Diagnostics Announces Launch of Proposed Public Offering • PR Newswire (US) • 01/16/2024 12:45:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/16/2024 12:18:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:03:07 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM